Borderline-Tumoren des Ovars

• Literatur

• 1 Taylor H. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929; 48: 204-230
• 2 International Federation of Obstetrics and Gynecology. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1-7
• 3 Serov SF, Scully RE. International Classification of Tumours. Vol. 9. Histological Typing of Ovarian Tumors. Geneva: World Health Organization; 1973
• 4 Scully RE. World Health Organization International Classification of Tumours. Histological Typing of Ovarian Tumors. Berlin, Heidelberg, New York, Tokio: Springer; 1999
• 5 Kommoss F, Richter B, Breitbach GP. Borderline-Tumoren des Ovars. Gynäkologe 2001; 34: 1003-1012
• 6 du Bois A, Burges A, Emons G et al. In: Schmalfeldt B, Pfisterer J, Hrsg. Interdisziplinäre S2 k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. München: W. Zuckschwerdt Verlag, Kommission Ovar der AGO e. V.; 2007
• 7 Tyler jr. CW, Lee NC, Robboy SJ et al. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?. Am J Obstet Gynecol 1991; 164: 65-70
• 8 Sengupta PS, Shanks JH, Buckley CH et al. Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer 2000; 82: 760-762
• 9 Leitao jr. MM, Boyd J, Hummer A et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004; 28: 147-159
• 10 Kommoss S, Pfisterer J, Reuss A et al. Specialized pathology review in patients with ovarian cancer: Results from a prospective study. Int J Gynecological Cancer 2013; [accepted for publication]
• 11 Mehnert A, Vehling S, Hocker A et al. Demoralization and depression in patients with advanced cancer: validation of the German version of the demoralization scale. J Pain Symptom Manage 2011; 42: 768-776
• 12 Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July–31 December 1969 and 1 July–31 December 1979. Int J Gynecol Pathol 1982; 1: 3-16
• 13 Auranen A, Grenman S, Makinen J et al. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol 1996; 144: 548-553
• 14 Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1204-1211
• 15 Gotlieb WH, Friedman E, Bar-Sade RB et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998; 90: 995-1000
• 16 Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31: 1420-1424
• 17 Sherman ME, Mink PJ, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004; 100: 1045-1052
• 18 du Bois A, Ewald-Riegler N, de Gregorio N et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 2013;
• 19 Gotlieb WH, Flikker S, Davidson B et al. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998; 82: 141-146
• 20 Tazelaar HD, Bostwick DG, Ballon SC et al. Conservative treatment of borderline ovarian tumors. Obstet Gynecol 1985; 66: 417-422